Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
@article{Lipsky2000InfliximabAM, title={Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.}, author={Peter E. Lipsky and D{\'e}sir{\'e}e Mfm van der Heijde and E. William St. Clair and Daniel E. Furst and F. C. Breedveld and Joachim Robert Kalden and Josef S. Smolen and Michael H. Weisman and Paul Emery and Marc Feldmann and Gregory R. Harriman and Ravinder Nath Maini}, journal={The New England journal of medicine}, year={2000}, volume={343 22}, pages={ 1594-602 } }
BACKGROUND
Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known.
METHODS
We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-alpha, in intravenous doses of 3 or 10 mg per kilogram of body…
3,041 Citations
Infliximab in the treatment of rheumatoid arthritis
- Medicine, BiologyBiologics : targets & therapy
- 2009
Infliximab was the first monoclonal antibody to human necrosis factor alpha (TNFα) developed for treating rheumatoid arthritis and has been shown to reduce joint inflammation and to slow radiographic progression, in both clinical and non-clinical responders.
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
- Medicine, BiologyDrug safety
- 2003
Recent reports underscore the need for caution and close surveillance with the administration of TNF inhibitors, particularly given that strategies aimed at preventing toxicity remain unproven.
Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
- MedicineArthritis and rheumatism
- 2011
The preliminary safety profile of rituximab in combination with a TNF inhibitor and MTX was consistent with the safety profile in other RA trials without a T NF inhibitor, with no new safety signals observed.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
- MedicineArthritis and rheumatism
- 2004
For patients with active RA in its early stages, combination therapy with MTX and infliximab provides greater clinical, radiographic, and functional benefits than treatment withMTX alone.
Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.
- MedicineDrugs
- 2005
Current data suggest that infliximab may be cost effective, especially when long-term clinical outcomes and burden of the diseases are taken into account, and more robust, prospective pharmaco-economic studies are required to better ascertain the cost effectiveness of inflIXimab.
Ten years of infliximab: insights from clinical trials in rheumatoid arthritis.
- MedicineEuropean journal of pharmacology
- 2009
Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases
- Medicine, BiologyMolecular biotechnology
- 2001
Evidence to date support the hypothesis that there are 2 particularly important mechanisms of action; deactivation of the proinflammatory cytokine cascade at the site of inflammation and diminished recruitment of inflammatory cells from blood to the rheumatoid joint.
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
- MedicineArthritis and rheumatism
- 2005
Even in patients without clinical improvement, treatment with infliximab plus MTX provided significant benefit with regard to the destructive process, suggesting that in such patients these 2 measures of disease are dissociated.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
- MedicineThe New England journal of medicine
- 2005
Abatacept produced significant clinical and functional benefits in patients who had had an inadequate response to anti-TNF-alpha therapy, including a clinically meaningful improvement in physical function.
Anti-TNFalpha therapy for rheumatoid arthritis: an update.
- Medicine, BiologyInternal medicine
- 2003
For patients with established and early RA, anti-TNF therapies set a new standard for symptom control and joint protection.
References
SHOWING 1-10 OF 40 REFERENCES
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
- MedicineThe Lancet
- 1999
Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
- MedicineThe Journal of rheumatology
- 2000
A single infusion of 5 to 20 mg/kg infliximab significantly decreases the signs and symptoms of RA compared to placebo in patients with active disease receiving MTX.
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
- MedicineThe New England journal of medicine
- 1997
In this three-month trial TNFR:Fc was safe, well tolerated, and associated with improvement in the inflammatory symptoms of rheumatoid arthritis.
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
- MedicineThe New England journal of medicine
- 1999
In patients with persistently active rheumatoid arthritis, the combination of etanercept and methotrexate was safe and well tolerated and provided significantly greater clinical benefit than metotrexate alone.
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
- Medicine, BiologyThe Lancet
- 1994
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
- MedicineArthritis and rheumatism
- 1998
Multiple infusions of cA2 were effective and well tolerated, with the best results occurring at 3 and 10 mg/kg either alone or in combination with MTX in approximately 60% of patients with active RA despite therapy with low-dose MTX.
The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.
- MedicineArthritis and rheumatism
- 1986
Toxicity was noted at some time in 26 of 29 patients (90%), but reactions universally became mild and tolerable after adjustment of the dosage, and there was a significant reduction in mean prednisone dosage.
Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
- MedicineArchives of internal medicine
- 1999
Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to Those with methotrexate treatment.
Efficacy of low-dose methotrexate in rheumatoid arthritis.
- MedicineThe New England journal of medicine
- 1985
It is concluded that this trial provides evidence of the short-term efficacy of methotrexate in rheumatoid arthritis, but the mechanism of action is unknown and longer trials will be required to determine the ultimate safety and effectiveness of this drug.
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
- Biology, MedicineJournal of immunology
- 1999
In vivo administration of anti-TNF-alpha Ab results in the rapid down-regulation of a spectrum of cytokines, cytokine inhibitors, and acute-phase proteins, consistent with the concept of a cytokine-dependent cytokine cascade.